$ARAY

Accuray Inc. (ARAY) completed a financing deal with TCW, reducing debt, adding capital, and waiving financial covenants until 2027. TCW exchanged $40M in loans for preferred stock and invested $15M. The company also executed a 1-for-40 reverse stock split. This transaction supports Accuray's strategic transformation plan.

Accuray reported Q1 2026 revenue of $86.52M, down 8% YoY, with net income of $10.13M, driven by a debt-extinguishment gain. Product revenue fell 26%, while service revenue rose 4%. Americas and China saw declines, but EIMEA grew 9%. Gross margin increased to 30.1%.

Accuray Inc. (NASDAQ:ARAY) approved a 1-for-40 reverse stock split, effective Nov. 9, 2026. The split aims to boost the stock price and comply with Nasdaq's minimum bid price requirement. Outstanding shares will reduce from 120.2M to 3M, with no fractional shares issued. Computershare Trust Company is the exchange agent.

ACCURAY INC (ARAY) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Accuray Announces 1-for-40 Reverse Stock Split MADISON, Wis., Nov. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that its Board of Directors has approved a 1-for-40 reverse stock split of the Company’s common stock and a corresponding de

Accuray reported a 26% decline in product sales but a 4% increase in service revenue to $59.2 million. Service gross margin rose 120 basis points to 35.1%. Operating expenses fell 29% excluding a $62.6 million goodwill impairment charge. The company signed agreements with RaySearch and Samsung NeuroLogica. Total revenue was $103.2 million, with a net income of $13 million. Accuray did not provide formal guidance for fiscal 2027, focusing on execution and commercial performance.

Accuray director Mika Nishimura will not seek re-election and will leave the board after the 2026 annual meeting. She will continue as Compensation Committee Chair until then. The departure is not due to any disagreement with the company or board, according to the SEC filing.

ACCURAY INC (ARAY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (a) On October 8, 2026, Mika Nishimura, a Class II director of Accuray Incorporated (the “Company”), informed the Company’s

Accuray (ARAY) stockholders approved financing-related proposals, enabling transactions with TCW Asset Management, including debt exchange, equity investment, and a reverse stock split. The company also appointed Richard A. Meier to its board. The moves aim to strengthen Accuray's financial position and support long-term value creation.

Accuray (ARAY) and Samsung NeuroLogica have partnered to advance volumetric imaging for the CyberKnife System. The collaboration aims to enhance treatment efficiency and decision-making, addressing customer priorities. Key clinicians highlighted the potential benefits for various cancer treatments. The partnership is part of Accuray's strategy to accelerate innovation through targeted collaborations.

Accuray (ARAY) has agreed to an $8 million deal with RaySearch to integrate their technologies, accelerating online adaptive radiation therapy. The collaboration focuses on Accuray's Radixact and CyberKnife platforms, aiming to enhance personalized treatments. Accuray's transformation plan has already exceeded cost and margin improvement targets by $20 million for fiscal 2026. Risks include slow adoption and third-party dependency on RaySearch. Institutional investment in ARAY has increased, wit